The effect of rosiglitazone, peroxisome proliferator-activated receptor gamma agonist on human telomerase reverse transcriptase expression in HEC-1A cell

Abstract

OBJECTIVE: The objective of this study was to investigate the effect of rosiglitazone, PPAR gamma agonist on hTERT(human telomerase reverse transcriptase) expression, ER(estrogen receptor) translocation into nucleus and ERK phosphorylation in HEC-1A cells.DESIGN: Telomerase, the specialized reverse transcriptase enzyme that elongates telomeres and synthesizes telomeric DNA, is increased in most cancer cells. Telomere shortening with each cell division, leading to limitless replication potential. PPAR gamma can suppress the cell growth in many cancer cells through various signal pathway. Therefore, we evaluated whether PPAR gamma has influence on hTERT expression.MATERIALS AND METHODS: HEC-1A cell was obtained from the American Type Culture Collection. After treatment of rosiglitazone, PPAR gamma agonist, hTERT expression, ERK phosphorylation and ER nuclear translocation were examined by western blotting in HEC-1A.RESULTS: The expression of hTERT was decreased in human endometrial cancer cell by treatment with rosiglitazone, PPAR gamma agonist. Also, decrements of ERK phosphorylation and ER beta nuclear translocation were observed.CONCLUSIONS: These results suggest that PPAR gamma plays an important role in the HEC-1A cell proliferation by hTERT expression. OBJECTIVE: The objective of this study was to investigate the effect of rosiglitazone, PPAR gamma agonist on hTERT(human telomerase reverse transcriptase) expression, ER(estrogen receptor) translocation into nucleus and ERK phosphorylation in HEC-1A cells. DESIGN: Telomerase, the specialized reverse transcriptase enzyme that elongates telomeres and synthesizes telomeric DNA, is increased in most cancer cells. Telomere shortening with each cell division, leading to limitless replication potential. PPAR gamma can suppress the cell growth in many cancer cells through various signal pathway. Therefore, we evaluated whether PPAR gamma has influence on hTERT expression. MATERIALS AND METHODS: HEC-1A cell was obtained from the American Type Culture Collection. After treatment of rosiglitazone, PPAR gamma agonist, hTERT expression, ERK phosphorylation and ER nuclear translocation were examined by western blotting in HEC-1A. RESULTS: The expression of hTERT was decreased in human endometrial cancer cell by treatment with rosiglitazone, PPAR gamma agonist. Also, decrements of ERK phosphorylation and ER beta nuclear translocation were observed. CONCLUSIONS: These results suggest that PPAR gamma plays an important role in the HEC-1A cell proliferation by hTERT expression.